Craig Maxwell, Global Head of Cell Therapy at AstraZeneca, shared on LinkedIn:
“Looking back on ACR2026 last week, it was fantastic to see all the progress on show. A highlight for me was seeing data from our ongoing cell therapy research.
Seeing our cell therapy research presented to the rheumatology community speaks to just how far this field has come and the rapid pace of innovation. Cell therapy is already helping to change outcomes for people with certain blood cancers – the question is now how we can extend that potential to people living with autoimmune diseases.
At AstraZeneca, our ambition is to realise the curative potential of cell therapy across a wide range of diseases spanning oncology, autoimmune and rare disease, and it’s inspiring to see this ambition coming to life!
Find out more on how we’re pioneering cell therapy here”

You can also read: